![Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study](https://icap.columbia.edu/wp-content/uploads/cancer_cells_melanoma_1200x900-1080x675.jpg)
ART - antiretroviral therapy
![Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study](https://icap.columbia.edu/wp-content/uploads/cancer_cells_melanoma_1200x900-1080x675.jpg)
![Patient feedback surveys among pregnant women in Eswatini to improve antenatal care retention](https://icap.columbia.edu/wp-content/uploads/BP_clinic_SA_1200x900-1080x675.jpg)
Patient feedback surveys among pregnant women in Eswatini to improve antenatal care retention
Teasdale CA, Geller A, Shongwe S, Mafukidze A, Choy M, Magaula B, Yuengling K, King K, De Gusmao EP, Ryan C, Ao T, Callahan T, Modi S, Abrams EJ. PLoS One. 2021 Mar 24;16(3):e0248685. doi: 10.1371/journal.pone.0248685. PMID: 33760864. Abstract Background: Uptake and...![February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study](https://icap.columbia.edu/wp-content/uploads/ring_1200x900-100-1080x675.jpg)
February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Article: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study Published in: Lancet HIV. 2021;8(2):e87-e95 https://doi.org/10.1016/S2352-3018(20)30304-0 Authors: Baeten JM, Palanee-Phillips T,...![January 2021: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results](https://icap.columbia.edu/wp-content/uploads/april-may-2020-jc-header-1080x675.png)
January 2021: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results
Article and Study Summary Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Published in: Lancet. 2020;396 (10267):1994-2005...![Implementation of tuberculosis preventive treatment among people living with HIV, South Sudan](https://icap.columbia.edu/wp-content/uploads/TBT-x-ray_1200x900-100-1080x675.jpg)